Pathogenesis and management of dialysis-related amyloid bone disease

Masaomi Nangaku, Toshio Miyata, Kiyoshi Kurokawa

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)


Dialysis-related amyloidosis (DRA) is a major complication of chronic renal failure and long-term renal replacement therapy. β2-Microglobulin is a major constituent of amyloid fibrils in DRA. Amyloid deposition can present as carpal tunnel syndrome, destructive arthropathy, or subchondral bone erosions and cysts. A definitive diagnosis of DRA can only be made using histological findings, but various analytical imaging methods often support diagnosis. Therapy of an established DRA is limited to symptomatic approaches and surgical removal of amyloid deposits. High-flux biocompatible dialysis membranes can be used to delay DRA development. Recent studies have suggested a pathogenic role for a new modification of β2-microglobulin in DRA. Increased carbonyl compounds modify proteins, which leads to the augmentation of advanced glycation and lipoxidation end products. Thus, uremia might be a state of carbonyl overload with potentially damaging proteins, leading to a new modification of β2-microglobulin in amyloid fibrils and development of DRA.

Original languageEnglish
Pages (from-to)410-415
Number of pages6
JournalAmerican Journal of the Medical Sciences
Issue number6
Publication statusPublished - 1999 Jun
Externally publishedYes


  • Dialysisamyloidosis
  • Renal osteodystrophy
  • Uremia
  • β2-microglobulin

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Pathogenesis and management of dialysis-related amyloid bone disease'. Together they form a unique fingerprint.

Cite this